Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Avalyn Pharma (AVLN): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow AVLN for free
Share

Sections with a free account

5 concentrated managers hold it (+5 vs last quarter) with a median weight of 0.3%.

Who owns Avalyn Pharma?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): FMR, 13.2% (13G/A filed Aug 6, 2026), Novo Holdings A/s, 8.8% (13G filed Aug 14, 2026), SR One Capital Management, 7.5% (13D filed May 8, 2026), Perceptive Advisors, 6.0% (13G filed May 7, 2026) and Montanova Capital, 5.6% (13D filed May 8, 2026). George Simeon is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were FMR (13.2% of the shares), Novo Holdings A/s (8.8%) and SR One Capital Management (7.5%).

Which institutions hold the most Avalyn Pharma shares?

Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:

  1. 1. FMR: 13.2%
  2. 2. Novo Holdings A/s: 8.8%
  3. 3. SR One Capital Management: 7.5%
  4. 4. Perceptive Advisors: 6.0%
  5. 5. Montanova Capital: 5.6%
  6. 6. NVP Associates: 5.1%
  7. 7. Wellington Management Group LLP: 5.0%
  8. 8. Price T Rowe Associates: 3.9%
  9. 9. Catalio Capital Management: 3.8%
  10. 10. T. Rowe Price Investment Management: 3.6%

How much of Avalyn Pharma do institutions own?

The 93 institutions that file 13F reported 100.0% of the shares as of Jun 30, 2026.

Sources:13G/A by FMR (Aug 6, 2026) ↗13G by Novo Holdings A/s (Aug 14, 2026) ↗13D by SR One Capital Management (May 8, 2026) ↗13G by Perceptive Advisors (May 7, 2026) ↗13D by Montanova Capital (May 8, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (Jun 2, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Well-known investors holding it

George Soros 13F (Q2 2026)

Concentrated managers
5
All 13F: 93
Consensus
13/100
across 5 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$32.92
reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (0 → 5): 5 opened · 0 exited = +5

Net flow in the quarter: +$62.2M (+1.9 M shares) · bought $62.2M and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Other relevant holders

Filers with $100M or more in the stock that do not count as concentrated managers because of their type: they are left out of the counts, the consensus and the accumulation.

Largest holders of AVLN (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 100.0% of the shares · top 10: 62.5% · in index firms: 6.8% of the institutional total

Shares reported by the 93 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (Jun 2, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Fundamentals

Balance sheet only, for now. AVLN has not yet filed its first annual report (10-K) with the SEC, so there are no 12-month figures (revenue, margins, earnings and cash flow). We show the balance sheet from its latest filing; once the 12-month figures are available, this section fills in automatically.

Balance sheet as of Jun 30, 2026
Cash and equivalents
$264M
Investments
$149M
Total debt
$14.8M
Net cash
$399M
Shareholders' equity
$398M

Balance sheet figures the company filed with the SEC (10-Q or 10-K), in dollars. Net debt = total debt − cash − investments; when negative, the company has more cash than debt (net cash). How each figure is calculated

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Sep 16, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow AVLN for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow AVLN